Navigation Links
Expensive arthritis treatment no better than steroid therapy
Date:11/10/2012

A randomized, double-blind clinical trial by researchers at Hospital for Special Surgery has revealed that corticosteroids are more effective than the more expensive treatment, hylan G-F 20 (Synvisc One, Genzyme Biosurgery), in providing pain relief to patients with thumb arthritis. The study also showed that both of these commonly used treatments provided clinically meaningful pain relief, but so did a placebo injection.

"On average, each of the therapies resulted in clinically meaningful improvement in pain," said Lisa Mandl, M.D., MPH, a rheumatologist at Hospital for Special Surgery, in New York City, who led the study. "What this study suggests is that a number of different injectable treatments might be effective for patients who have pain in their thumb and that the one that appeared to be the most effective was corticosteroids." The study will be reported at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, to be held Nov. 9-14, in Washington D.C.

The new study is the first large randomized clinical trial in patients with carpometacarpal (CMC) osteoarthritis (thumb arthritis). The study compared a placebo, an injection of a local anesthetic called bupivacaine, with two commonly used injectable treatments: a corticosteroid called triamcinolone acentoide and hylan G-F 20, which is made from a natural substance that lubricates and decreases inflammation in the joints. CMC osteoarthritis, caused by regular wear and tear, is common in individuals over 60. It occurs in 80% of women who are 80 years of age or older.

The researchers enrolled 200 patients with thumb arthritis and randomized them to receive bupivacaine, hylan G-F 20, or triamcinolone. The average age of patients in the study was 66.5 and roughly 70% were female. Over the 26-week study, pain, as measured by the Visual Analogue Scale (VAS), showed a statistically and clinically significant improvement in all treatment groups. Each group gained slightly more than an average of 10 points; an improvement in 10 points is clinically meaningful. Patients who received corticosteroids had slightly greater improvements in pain compared to patients who received Hylan G-F 20. No treatment arm had clinically meaningful improvements in function.

"Overall, this was a negative trial," said Dr. Mandl. "If you compare the three treatments to each other, neither the steroid or Synvisc provided better pain relief than bupivacaine. Bupivacaine shouldn't do anything. It should numb and wear out in 20 minutes, but even that seems to help some people. What this suggests is that maybe the injection itself is making people feel better."

The researchers say that clinicians can consider trying any of the three treatments in their patients with CMC. "It may be that steroids are the most effective, so I would probably try steroids first. If that didn't work, then I would try hylan G-F 20. If patients were hesitant to try either steroids or hylan G-F 20, I'd even try bupivacaine," said Dr. Mandl.

The researchers point out that clinicians need to weigh the pros and cons of the different treatments. For example, Hylan G-F 20 is usually prescribed every six months and could be used repeatedly over time. Steroid injections, however, if given repeatedly, could end up damaging the joint further. Hylan G-F 20 costs in the ballpark of $600 for each treatment, whereas corticosteroids cost roughly $15 per treatment.

Dr. Mandl points out that even patients with very severe osteoarthritis benefited from the treatments. Arthritis severity is measured by the amount of cartilage left in a joint; in Grade 4, there is no cartilage left and bone is grinding against bone. "Even if you have a patient with terrible arthritis, it is worth trying one of these therapies," said Dr. Mandl. "There is no other therapy besides surgery for these people once they have failed other conservative measures."


'/>"/>
Contact: Phyllis Fisher
phyllis.fisher@gmail.com
212-606-1724
Hospital for Special Surgery
Source:Eurekalert  

Related medicine news :

1. Expensive, Drug-Emitting Stents May Be Overused: Study
2. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
3. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
4. Gastro Woes Often Strike Rheumatoid Arthritis Patients
5. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
6. One-third of adult Americans with arthritis battle anxiety or depression
7. Children with juvenile arthritis have higher rates of bacterial infection
8. Arthritis in Children Linked to Infections
9. Rising Obesity Rates Might Mean More Rheumatoid Arthritis
10. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
11. New biomarker test predicts arthritis at much earlier stage, MU researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Expensive arthritis treatment no better than steroid therapy
(Date:5/26/2016)... ... ... In Madeira Beach Florida, a small town with 4,300 residents on a ... Madeira Beach United, to oppose two development projects undertaken by their city government that ... rise urban environment. , According to the Tampa Bay Times on May ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and ... , furniture that may support women during pregnancy. Potential benefits of using the Stance ... rest and comfort and healthier levels of sitting and standing. , Need for the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award with ... second for Memorial Healthcare System, recognizes its commitment to emergency stroke care ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, a ... video highlighting one of the many supplemental program options offered at their rehabilitation ... 5 th Degree Black Belt in the Shorin-ryu style of Karate that originated ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology: